Results of a randomised phase II study of cisplatin plus 5-fluorouracil versus cisplatin plus 5-fluorouracil with α-interferon in metastatic pancreatic cancer: An EORTC gastrointestinal tract cancer group trial

European Journal of Cancer

Volumn 38, Issue 5, 2002, Pages 648-653

  Wagener, D J T ^a   Wils, J A ^b   Kok, T C ^c   Planting, A ^c   Couvreur, M L ^d   Baron, B ^d  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LAURENTIUS HOSPITAL   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d EORTC DATA CENTER   (Belgium)

Author keywords

Cisplatin plus 5 fluorouracil; Cisplatin plus 5 fluorouracil plus interferon; Pancreatic cancer; Phase II study

Indexed keywords

ALPHA INTERFERON; CISPLATIN; FLUOROURACIL;

ADULT; AGED; ARM; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG INFUSION; FEMALE; GASTROINTESTINAL CARCINOMA; HEART ARRHYTHMIA; HUMAN; HYPOMAGNESEMIA; MALE; METASTASIS; NEUROTOXICITY; PANCREAS; PANCREAS CARCINOMA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TOXICITY;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0036207102     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00319-7     Document Type: Article

References (25)

1. Multimodality treatment of locally advanced pancreatic cancer
2. Chemotherapy of adenoca of the pancreas
3. Cancer of the pancreas
4. No standard treatment is available for advanced pancreatic cancer
5. Phase II trial with ifosfamide in pancreatic cancer
6. Activity of cisplatin in adenocarcinoma of the pancreas
7. Efficacy of combined 5FU and CDDP in advanced pancreatic adenocarcinoma
8. Augmentation of cytotoxicity of chemotherapy by human α-interferons in human non-small cell lung cancer xenografts
9. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: A review
10. Potentiation of cisplatin by α-Interferon in advanced non-small cell lung cancer (NSCLC): A phase II study
11. Clinical update on the role of fluorourarcil and recombinant interferon alfa-2a in the treatment of colorectal carcinoma
12. Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma
13. Interferon alfa-2a and 5-fluorouracil for advanced colorectal carcinoma: Assessment of activity and toxicity
14. Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: An eastern cooperative oncology group study
15. Phase II trial of 5-fluorouracil and recombinant interferon alpha-2a in advanced colorectal cancer
16. Interaction of gamma-interferon and 5-fluoro-uracil in the H630 human colon carcinoma cell line
17. Fluoro-uracil and recombinant α-2A-interferon: An active regimen against advanced colorectal carcinoma
18. Pancreatic cancer in the Syrian hamster induced by N-nitroso bis (2-oxypropyl)-amine: Carcinogenic effect with epidermal growth factor
19. Augmentation of chemically induced pancreatic and bronchial cancers by epidermal growth factor
20. Autocrine growth factors and cancer
21. Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer cells
22. Nonparametric estimation form incomplete observations
23. Royal Marden Phase III trial of fluorouracil with of without interferon alpha-2b in advanced colorectal cancer
24. Surgical adjuvant therapy of rectal carcinoma: A controlled evaluation of fluorouracil, leucovorin and radiation therapy with and without interferon α-2 b
25. Improving the quality of reporting of randomised controlled trials: The CONSORT statement